Aethlon Medical (AEMD) Proxy filing summary

Executive summary

• Annual Meeting scheduled for October 1, 2026, will be held virtually to maximize shareholder participation and convenience.

• Proxy materials, including the Proxy Statement and Annual Report, were distributed to shareholders of record as of August 10, 2026.

• Shareholders are encouraged to vote on key proposals, with the Board recommending approval for most items.

Voting matters and shareholder proposals

• Shareholders will vote on 11 proposals, including director elections, auditor ratification, equity issuances, amendments to the equity plan, and capital structure changes.

• Proposals include authorizing new shares, preferred stock, and future financing flexibility, as well as an advisory vote on executive compensation.

• Board recommends voting “FOR” Proposals 1, 2, 3, 4, 6, 7, 8, 9, and 10.

• Shareholder proposals for the next annual meeting must be submitted by April 13, 2027, for inclusion.

Board of directors and corporate governance

• Board consists of five members, four of whom are independent under Nasdaq rules.

• Board committees include Audit, Compensation, and Nominating and Corporate Governance, each with defined responsibilities and independent chairs.

• Board members have diverse backgrounds in finance, medicine, and biotechnology.

• Code of Ethics and anti-hedging/pledging policies are in place for directors, officers, and employees.